Abstract #3753

White matter free water content at different stages of Alzheimer’s disease

Matthieu Dumont¹, Koene R. A. Van Dijk², Felix C. Morency¹, Jean-Christophe Houde^1,3, Pierre-Marc Jodoin^1,4, Zhiyong Xie², Cici Bauer⁵, Tarek A. Samad⁶, Maxime Descoteaux^1,3, and James A. Goodman²

¹Imeka Solutions, Inc, Sherbrooke, QC, Canada, ²Clinical & Translational Imaging, Pfizer, Inc, Cambridge, MA, United States, ³Sherbrooke Connectivity Imaging Laboratory (SCIL), University of Sherbrooke, Sherbrooke, QC, Canada, ⁴Computer Science, University of Sherbrooke, Sherbrooke, QC, Canada, ⁵ECD Non-Clinical Statistics, Pfizer, Inc, Cambridge, MA, United States, ⁶Internal Medicine Research Unit, Pfizer, Inc, Cambridge, MA, United States

Recent evidence shows that neuroinflammation plays a role in many neurological diseases including Alzheimer’s disease (AD), and that free water (FW) diffusion imaging can be sensitive to this phenomenon. We processed MRI data from the ADNIGO and ADNI2 databases with a state-of-the-art processing pipeline that uses T1 weighted (T1w), diffusion weighted (DW), and fluid-attenuated inversion recovery (FLAIR) scans to extract FW fractional volume in normal appearing white matter. We call this metric relative FW volume (rFW volume). We demonstrate for the first time that rFW volume in white matter is higher for subjects with greater cognitive impairments.

This abstract and the presentation materials are available to members only; a login is required.

Join Here